Research Programs

Nucleoside Discovery Programs

We believe nucleoside analogs are well suited to treat viral diseases because they can be designed to be highly specific and potent, are relatively simple to manufacture, and have the potential for oral administration. Nucleoside analog drugs have a well-established regulatory history, with 14 nucleoside analogs approved by the FDA for the treatment of HBV, HCV or HIV. In addition to clevudine, R7128, Racivir and DFC, we also have other nucleoside analog discovery programs focused on HIV and HCV. Our scientific team of virologists, biologists and nucleoside chemists has experience discovering and developing nucleoside analog drugs for antiviral indications. Collectively, our management team’s product development experience includes 25 New Drug Applications, or NDAs. Our discovery platform includes a library of nucleoside analogs and a collection of viral and cellular assays that we use to evaluate potential new product candidates.